These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 18839328)

  • 1. Serum fibroblast growth factor-23 levels in chronic haemodialysis patients.
    Ibrahim S; Rashed L
    Int Urol Nephrol; 2009; 41(1):163-9. PubMed ID: 18839328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of fibroblast growth factor-23 in chronic kidney disease.
    Westerberg PA; Linde T; Wikström B; Ljunggren O; Stridsberg M; Larsson TE
    Nephrol Dial Transplant; 2007 Nov; 22(11):3202-7. PubMed ID: 17567652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibroblast growth factor-23 is associated with parathyroid hormone and renal function in a population-based cohort of elderly men.
    Marsell R; Grundberg E; Krajisnik T; Mallmin H; Karlsson M; Mellström D; Orwoll E; Ohlsson C; Jonsson KB; Ljunggren O; Larsson TE
    Eur J Endocrinol; 2008 Jan; 158(1):125-9. PubMed ID: 18166826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism.
    Koizumi M; Komaba H; Nakanishi S; Fujimori A; Fukagawa M
    Nephrol Dial Transplant; 2012 Feb; 27(2):784-90. PubMed ID: 21730210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased circulating levels of FGF23: an adaptive response in primary hyperparathyroidism?
    Witteveen JE; van Lierop AH; Papapoulos SE; Hamdy NA
    Eur J Endocrinol; 2012 Jan; 166(1):55-60. PubMed ID: 21984611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term sevelamer treatment lowers serum fibroblast growth factor 23 accompanied with increasing serum Klotho levels in chronic haemodialysis patients.
    Lin HH; Liou HH; Wu MS; Lin CY; Huang CC
    Nephrology (Carlton); 2014 Nov; 19(11):672-8. PubMed ID: 25113414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dialysis vintage and parathyroid hormone level, not fibroblast growth factor-23, determines chronic-phase phosphate wasting after renal transplantation.
    Tomida K; Hamano T; Ichimaru N; Fujii N; Matsui I; Nonomura N; Tsubakihara Y; Rakugi H; Takahara S; Isaka Y
    Bone; 2012 Oct; 51(4):729-36. PubMed ID: 22796419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of vitamin D status on the relative increase in fibroblast growth factor 23 and parathyroid hormone in chronic kidney disease.
    Taal MW; Thurston V; McIntyre NJ; Fluck RJ; McIntyre CW
    Kidney Int; 2014 Aug; 86(2):407-13. PubMed ID: 24429404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum level of fibroblast growth factor 23 in maintenance renal transplant patients.
    Sánchez Fructuoso AI; Maestro ML; Pérez-Flores I; Valero R; Rafael S; Veganzones S; Calvo N; De la Orden V; De la Flor JC; Valga F; Vidaurreta M; Fernández-Pérez C; Barrientos A
    Nephrol Dial Transplant; 2012 Nov; 27(11):4227-35. PubMed ID: 23144073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibroblast growth factor 23 and soluble klotho in children with chronic kidney disease.
    Wan M; Smith C; Shah V; Gullet A; Wells D; Rees L; Shroff R
    Nephrol Dial Transplant; 2013 Jan; 28(1):153-61. PubMed ID: 23180879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Associations between the levels of sclerostin, phosphate, and fibroblast growth factor-23 and treatment with vitamin D in hemodialysis patients with low intact PTH level.
    Asamiya Y; Yajima A; Shimizu S; Otsubo S; Tsuchiya K; Nitta K
    Osteoporos Int; 2015 Mar; 26(3):1017-28. PubMed ID: 25366373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cinacalcet treatment decreases plasma fibroblast growth factor 23 concentration in haemodialysed patients with chronic kidney disease and secondary hyperparathyroidism.
    Kuczera P; Adamczak M; Wiecek A
    Clin Endocrinol (Oxf); 2014 Apr; 80(4):607-12. PubMed ID: 24111496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of fibroblast growth factor 23 (FGF23) in the metabolism of phosphorus and calcium immediately after kidney transplantation.
    Sánchez Fructuoso AI; Maestro ML; Calvo N; De La Orden V; Pérez Flores I; Vidaurreta M; Valero R; Fernández-Pérez C; Barrientos A
    Transplant Proc; 2012 Nov; 44(9):2551-4. PubMed ID: 23146451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Administration of Ferric Citrate Hydrate Decreases Circulating FGF23 Levels Independently of Serum Phosphate Levels in Hemodialysis Patients with Iron Deficiency.
    Iguchi A; Kazama JJ; Yamamoto S; Yoshita K; Watanabe Y; Iino N; Narita I
    Nephron; 2015; 131(3):161-6. PubMed ID: 26551233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism.
    Kazama JJ; Gejyo F; Shigematsu T; Fukagawa M
    Ther Apher Dial; 2005 Aug; 9(4):328-30. PubMed ID: 16076376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated FGF23 levels are associated with impaired calcium-mediated suppression of PTH in ESRD.
    Wetmore JB; Santos PW; Mahnken JD; Krebill R; Menard R; Gutta H; Quarles LD
    J Clin Endocrinol Metab; 2011 Jan; 96(1):E57-64. PubMed ID: 20943782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deviations from the expected relationship between serum FGF23 and other markers in children with CKD: a cross-sectional study.
    Liu D; Alvarez-Elías AC; Wile B; Belostotsky V; Filler G
    BMC Nephrol; 2017 Jun; 18(1):204. PubMed ID: 28659167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of erythropoietin resistance and fibroblast growth factor 23 in dialysis patients: Results from the Japanese Dialysis Outcomes and Practice Patterns Study.
    Usui T; Zhao J; Fuller DS; Hanafusa N; Hasegawa T; Fujino H; Nomura T; Zee J; Young E; Robinson BM; Nangaku M
    Nephrology (Carlton); 2021 Jan; 26(1):46-53. PubMed ID: 32743932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Mineral metabolism in patients on chronic peritoneal dialysis].
    Ceballos O ML; Rojo L A; Azócar P M; Ibacache M MJ; Delucchi B A; Quiroz Z L; Irarrázabal M C; Delgado B I; Ugarte P F; Cano Sch F
    Rev Chil Pediatr; 2014 Feb; 85(1):31-9. PubMed ID: 25079181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.